Skip to main content

Table 4 Health characteristics of schoolchildren successfully retraced (i.e. pre and post treatment-n = 853)

From: The impact of single versus mixed schistosome species infections on liver, spleen and bladder morbidity within Malian children pre- and post-praziquantel treatment

 

Baseline

Post-treatment

 

Bamako

Koulikoro

Ségou

Bamako

Koulikoro

Ségou

 

(n = 273)

(n = 153)

(n = 427)

(n = 273)

(n = 153)

(n = 427)

Parasitology

% Uninfected

45.05 (< 0.001)a

14.38 (< 0.001)b

8.90 (< 0.001)c

64.10 (< 0.001)d **

32.68 (0.010)e **

40.05 (< 0.001)f **

% Infected with S. haematobium

43.96 (< 0.001)a

3.92 (< 0.001)b

57.38 (< 0.001) c

26.37 (< 0.001)d **

5.23 (< 0.001)e

35.36 (0.011) f **

% Infected with S. mansoni

1.10 (< 0.001)a

24.84 (< 0.001)b

4.22 (0.007)c

4.03 (< 0.001)d **

40.52 (< 0.001)e **

14.05 (< 0.001)f **

% Co-infected

9.89 (< 0.001)a

56.86 (< 0.001)b

29.51 (< 0.001)c

5.49 (< 0.001)d **

21.57 (0.002)e **

10.54 (0.013) f **

% Heavy S. haematobium infections

13.19 (0.040) a

7.19 (< 0.001) b

39.58 (< 0.001)

2.20 (0.161) c **

0.65 (< 0.001) e **

7.73 (< 0.001) f **

% Heavy S. mansoni infections

0.73 (< 0.001)

22.88 (0.005)

12.41 (< 0.001)

0.00 (< 0.001)

10.46 (0.003) **

2.81 (< 0.001) **

Liver Pathology as assessed by ultrasound (US) examination

% with abnormal liver image patterns

0.37 (0.316)a

0.00 (< 0.001)b

12.18 (< 0.001)c

0.37 (0.316)d

0.00 (< 0.001)e

12.88 (< 0.001)f

% with portal hypertension (as determined by positive PVD scores)

0.73 (0.585)a

1.31 (< 0.001)b

9.60 (< 0.001)c

5.49 (0.013)d **

13.07 (0.076)e **

7.73 (0.237)f

% with hepatomegaly (as determined by positive PSL scores from US)

0.37 (0.701)a

0.65 (0.085)b

2.34 (0.085)c

0.00 (0.316)d

0.65 (0.545)e

0.23 (0.317)f **

Liver + spleen pathology as assessed by clinical examination

% with hepatomegaly as assessed by MSL>2 cm

0.00 (0.316)a

0.65 (< 0.001)b

9.84 (< 0.001)c

0.00 (0.080)d

1.96 (0.291)e

0.70 (0.082)f **

% with hepatomegaly as assessed by MCL>2 cm

0.00 (0.316)a

0.65 (< 0.001)b

8.67 (< 0.001)c

0.00 (0.080)d

1.96 (0.291)e

0.70 (0.082)f **

% with splenomegaly as assessed by MCL>2 cm

0.73 (< 0.001)a

12.42 (< 0.001)b

27.17 (< 0.001)c

0.00 (0.023)d

3.27 (0.009)e **

8.43 (< 0.001)f **

% with splenomegaly as assessed by MAL>2 cm

0.73 (< 0.001)a

8.50 (< 0.001)b

25.06 (< 0.001)c

0.00 (0.043)d

2.61 (0.010)e **

7.26 (< 0.001)f **

Bladder Pathology as assessed by US examination

Bladder pathology (as determined by positive global scores from US)

8.42 (0.194)a

5.23 (< 0.001)b

22.95 (< 0.001)c

22.34 (0.057)d **

15.03 (< 0.001)e **

3.98 (< 0.001)f **

  1. ap-values comparing proportions reported between Bamako and Koulikoro at baseline in parentheses; b p-values comparing proportions reported between Koulikoro and Ségou at baseline in parentheses; c p-values comparing proportions reported between Bamako and Ségou at baseline in parentheses; d p-values comparing proportions reported between Bamako and Koulikoro at follow-up in parentheses; e p-values comparing proportions reported between Koulikoro and Ségou at follow-up in parentheses; f p-values comparing proportions reported between Bamako and Ségou at follow-up in parentheses; ** significant differences at α = 0.05 between baseline and post treatment paired proportions as indicated by McNemar's test
  2. US, ultrasound; PVD, portal vain diameters; PSL, parasternal line; MSL, mid-sternal line; MCL, mid-clavicular line; MAL, mid-axillary line